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A simple, rapid, sensitive, specific, eco-friendly and stability-indicating linear gradient liquid chromatographic method 
(RP-UHPLC) for simultaneous estimation of assay and its related compounds in Meropenem API samples is developed and 
validated. Chromatographic separation was achieved on Zorbax Eclipse plus C18, (100 x 4.6) mm, 3.5 µm RRLC short 
column and 10 mM potassium dihydrogen orthophosphate is used as buffer, buffer solution used as eluent A and buffer and 
acetonitrile combination 30: 70 v/v ratio used as eluent B and Agilent RRLC (UHPLC) system is used for analysis. The 
mobile phase flow rate was 1.0 ml/min, and the eluted compounds have been monitored at 220 nm for related substance 
method and 290 nm for assay method. Excellent resolution is obtained between Meropenem and its related compounds 
which were eluted within 10 min. The correlation co-efficient(r) is > 0.995 for both the methods from linearity data and 
percentage of recovery is 98.0 to 102.0 and 80.0 to 120.0 % for assay method and for related substance method, 
respectively. Sensitivity of the method is found to be less than 0.316 µg/ml. Peak homogeneity data for Meropenem in the 
chromatograms from the stressed samples are obtained by using photodiode array detector demonstrated the specificity of 
the method for analysis of Meropenem in presence of the degradation compounds. The performance of the method is 
validated according to the present ICH guidelines for specificity, limit of detection, limit of quantification, linearity, 
accuracy, precision, and robustness. 
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Meropenem, is (4R,5S,6S)-3-[[(3S,5S)-5-(dimethyl 
carbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl] 
-4-methyl-7-oxo-1-azabicyclo [3.2.0] hept-2-ene-
carboxylic acid, trihydrate (Fig. 1). It is a broad-
spectrum carbapenem antibiotic with wide range of
activity. It is used mainly for the treatment of serious
bacterial infections, including lower respiratory tract,
intra-abdominal, obstetric/gynecological, urinary tract,
skin structure, meningitis, cystic fibrosis and in febrile
neutropenia
1,2
. Meropenem is metabolized inside the
human body through hydrolysis to form the opened-
lactam ring product which is pharmacologically
inactive. In healthy volunteers, 70 % of the
administered dose is excreted unchanged in urine and
20 % as the open-ring metabolite and it is a new
parenteral carbapenem antibiotic with a very broad
spectrum of antibacterial activity against the majority
of gram-positive and gram-negative pathogens
3-6
.
Meropenem is frequently used in intensive care
units for treating severe infections caused by
organisms resistant to other antibiotics, such
Pseudomonas aeruginosa. As a β-lactam, its activity
is dependent upon the time during which 
plasma concentrations stay above the MIC of the 
offending organism, triggering its use by extended 
infusion administration
7-9
. It is more active in vitro 
than imipenem against Enterobacteriaceae and 
Pseudomonas aeruginosa, but less active against 
gram positive cocci. Meropenem is more stable to ring 
opening by human renal dehydropeptidase -I (DHP-I) 
than imipenem and consequently does not require 
concomitant administration of a DHP-1 inhibitor. This 
antibiotic has shown clinical efficacy in the treatment 
of a wide range of serious infections such as 
Fig. 1 — Chemical structure of Meropenem. 




intra-abdominal infections, urinary tract infections 
and lower respiratory tract infections including 
patients with cystic fibrosis. These sterile 
carbapenems are in very high demand and the 




Meropenem was patented in 1983 and it was 
approved for medical use in the United States in 1996. 
It is on the World Health Organization's List of 
Essential Medicines, the most effective and safe 
medicines needed in a health system. The wholesale 
cost in the developing world is between 3.44 and 
20.58 USD per one gram vial as of 2015. In the 
United Kingdom this amount costs the NHS about 
£16 in 2015
10-15
. The Meropenem was synthesized by 
various route of synthesis and selected compound 
synthesized by using MAP and Thiol intermediates 
compound by preparing protected Meropenem and 
followed by deprotection. The route of synthesis is 
given below in Fig. 2. An extensive literature survey 
revealed that there are certain methods reported for 
determination of Meropenem and its main metabolite 
(ICI-213689) in biological fluids, including high-
performance liquid chromatography (HPLC), 
capillary zone electrophoresis, microbiological assay 
and few quantitation of Meropenem in pharmaceutical 
dosage form by combination of HPLC and UV-visible 
spectrophotometer
16-26
. An official compendia method 
is available for related substances and assay 
determination in United States Pharmacopoeia (USP). 
This method was based on the mobile phase 
containing triethyl amine as organic modifier which 
required more stabilization time at lower wavelengths 
and shortens the column life, more over impurity C is 
not eluting in stated method
27
.  
In our knowledge and after an exhaustive  
literature survey, there is no evidence of availability 
of methods on stability indicating gradient UHPLC 
method for estimation of assay and its related 
compounds of Meropenem in bulk and its 
formulation. Consequently, the implementation of 
novel analytical methodology to determine the assay 
and its related compounds in API and its formulation 
is a challenge of the pharmaceutical analysis. The 
objectives of the research work is to develop a 
suitable gradient stability-indicating short run time 
UHPLC method for analysis of Meropenem in API 
samples and to validate the method for specificity, 
LOD, LOQ, linearity, precision, accuracy, and 
robustness to show the stability-indicating power  




Fig. 2 — Route of synthesis of Meropenem. 




Material and Methods 
 
Materials 
Meropenem reference standard was purchased 
from USP catalogue number 1392454, lot number 
was IOJ244 (USP Rockville, MD). Meropenem test 
sample and known impurity compounds (for 
specificity) were synthesized (impurity structures are 
shown in Fig. 3) at ecoLogic Technologies limited, 
Hyderabad, India. Acetonitrile and Potassium 
dihydrogen orthophosphate (HPLC–grade) were 
purchased from Merck Fine Chemicals (Mumbai, 
India). Sodium hydroxide (NaOH), hydrochloric acid 
(HCl) and hydrogen peroxide (H2O2) GR grade 
chemicals were also obtained from Merck Fine 
Chemicals (Mumbai, India). Milli-Q water is obtained 
from Millipore direct 8 l/h system. 
 
Apparatus 
The instrument Agilent 1260 Infinity series with a 
diode array detector (quaternary pump: G1311B, 
column thermostat: G1316B, Auto sampler with 
cooler: G1329B and G1330B and detector: G4212B) 
was used for the development of ultra-high 
performance liquid chromatographic method 
(UHPLC). The chromatographic data was recorded by 
using Chemstation (Agilent Technologies, Clara, US), 
peak purity of Meropenem was tested by using 
Waters Empower 3 software (Waters, US). A column, 
Zorbax Eclipse plus C18, (100 x 4.6) mm 3.5 µm 
RRLC, manufactured by Agilent (Agilent 
Technologies, Clara, US) was procured from LCGC 
India.  
 
Optimized chromatographic conditions 
The chromatographic separation was achieved on 
Zorbax Eclipse plus C18, (100 x 4.6) mm 3.5 µm 
RRLC column. In house prepared 10 mM potassium 
dihydrogen orthophosphate was used as buffer, eluent 
A is buffer solution and eluent B is a combination of 
buffer and acetonitrile in 30:70 v/v ratio with a linear 
gradient programme:time min / % B is 0/30, 5/90, 
9.5/90,10/30 and 15/30 at flow rate of 1.0 ml/min. 
The analysis was carried out at UV detection of  
220 nm for related substances determination and 290 
nm for assay determination and column temperature 
was maintained at 25 °C with 10.0 µl injection 
volume. Samples were diluted in eluent-A and B in 
1:1 ratio. 
 
Preparation of solutions 
Preparation of standard solution: Meropenem 
Standard solution is prepared about 1000 µg/ml for 
both assay and related compounds methods. 
Preparation of impurities stock solutions: 
Meropenem related compound stock solutions were 




Fig. 3 — Chemical structure of related compounds of Meropenem. 




Preparation of sample solutions: Sample solutions 
were prepared about 1000 µg/ml solution for both 
assay and related compounds methods. 
Preparation of spike sample solutions: Spike 
sample solutions were prepared by spiking impurities 
about 1 µg/ml. 
 
Specificity/Selectivity  
Specificity is the ability of the method to measure 
the analyte response in the presence of its potential 
impurities and a study was conducted to demonstrate 
the effective separation of degradants and stress studies 
were divided into two parts one is in liquid state and 
another one was solid state as described manner. 
 Liquid state stress study conditions were 
optimized as given below 
a) Acid hydrolysis using 0.1 N HCl at room 
temperature 
b) Base hydrolysis using 0.1 N NaOH at room 
temperature 
c) Oxidative hydrolysis using 3% H2O2 at room 
temperature 
 Solid state stress study conditions were optimized 
as given below 
a) Thermal stress at temperature 60 °C for 5 days 
b) Photolytic degradation under 
Ultraviolet light (200 watt hours/square meter),  
Visible light (1.2 million Lux h) 
 
Precision 
For related compound method six solutions 
containing Meropenem (100 µg/ml) were spiked with 
related compounds solutions 0.5 µg/ml (0.10% of 
Meropenem concentration). Chromatography was 
performed and value of %RSD was calculated 
considering peak area for Meropenem and each 
related compounds. Similarly, intermediate precision 
of the method was also evaluated by another analyst, 
on a different day in the same laboratory. 
For assay method six individual sample solutions 
were prepared Meropenem (1000 µg/ml) and 
calculated assay of the compound against standard 
solution and also checked % RSD for assay values for 
six determinations. Similarly, intermediate precision 
of the method was also evaluated by another analyst, 
on a different day in the same laboratory. 
 
Limit of detection and Limit of quantitation 
The limit of detection (LOD) and limit of 
quantitation (LOQ) for Meropenem and related 
compounds were determined. Precision study was 
also carried out at the LOQ level by injecting six 
(n=6) individual preparations and calculated the 
%RSD considering peak area for Meropenem and 
each related compounds. 
 
Linearity 
For the related compound determination method 
linearity was checked for related compound and 
Meropenem at lower concentration levels of 0.03% to 
0.2% (i.e., 0.3 µg/ml to 2 µg/ml). The responses were 
measured as peak areas and plotted against 
concentration. The similar experiment was performed 
for assay method linearity by preparing the standard 
concentrations 80% to 120% at assay concentration 
level (800 µg/ml to 1200 µg/ml). The calibration 
curve was drawn by plotting the each impurity peak 
area versus its corresponding concentration. The 
correlation co-efficient, slope and Y-intercept for each 
impurity were determined.  
 
Accuracy 
The accuracy of the assay method was evaluated in 
triplicate (n=3) at the concentration levels of 
Meropenem 800, 1000 and 1200 µg/ml (80%, 100% 
and 120%) and the % recovery was calculated at each 
level. Similarly accuracy of the related substances 
method evaluated in triplicate (n=3) at the 
concentration levels of each related compound about 
0.03%, 0.1% and 0.2% level and the %recovery was 
calculated for each related compound.  
 
Stability of the solution 
A sample solution of assay method and related 
substance method were checked at different time 
intervals up to 48 h by keeping solution at 5 °C and 
checked cumulative %RSD for the peak area of 
Meropenem and its related compounds.  
 
Results and Discussion 
 
Method development 
The main aim of the method is to develop a rapid 
and single chromatographic method for estimation of 
assay and its related compounds in Meropenem API 
samples. Meropenem UV spectrum was shown in  
Fig. 4. As Meropenem and related impurities are 
containing betalactum groups, based on pKa value 
and solubility of the compound, various compositions 
of mobile phase were screened. Meropenem and its 
degraded products peak shapes were not improved 
below pH 4, various pH and different brand C18 




columns were tried for the development and 
optimization, the best peak shapes and good retention 
were observed about pH 4.5. The chromatographic 
conditions were optimized in view of a stability 
indicating assay method, which can separate the drug 
from its degradation peaks with good resolution. 
Mobile phase consisting of phosphate buffer and 
acetonitrile, at a flow rate of 1.0 ml/min, was found to 
be satisfactory to obtain well-resolved peaks with 




All degradant peaks were resolved from 
Meropenem peak in the chromatograms of all 
stressed samples. The chromatograms of the stressed 
samples were evaluated for peak purity of 
Meropenem using Waters Empower software. For all 
forced degradation samples, the peak purity of 
Meropenem was passed as purity angle is less than 
the purity threshold with no purity flag. Thus, this 
method is considered to be stability indicating. 
According to stress study data, significant 
degradation was observed at acid and base 
hydrolysis and mild degradation was observed in 
oxidative hydrolysis. Similarly, mild degradation 
was observed in thermal and photolytic conditions 
and peak purity for Meropenem peak was passing in 
all the stressed samples and also there was no 
interference from degradation products from the 
analyte peak which are formed throughout the study. 
The assay of the Meropenem was quantitatively 
determined in all stress sample solutions against 
reference standard and the mass balance (%assay + 
% sum of all impurities + %sum of all degradation 
products) was tabulated in Table 1 and System 
suitability results are given in Table 2. A Typical 
chromatogram of system suitability & selectivty and 
stress study chromatograms (acid & base stress) are 
shown in Fig. 5 & 6. 
 
 
Fig. 4 — UV spectrum of Meropenem. 
 
Table 2 — System suitability results 
Name Retention time (min) Resolution (Rs) by Tangent method (USP) USP Theoretical Plates USP Tailing factor (T) 
Meropenem 4.86 - 110000 1.07 
Impurity-B 6.75 - 48000 1.19 
Impurity-C 7.54 1.9 98000 1.02 
Impurity-A 8.49 2.2 83567 1.02 
 
 
Table 1 — Forced degradation results 








Acid hydrolysis using 
0.1N HCl (at 25°C) 
2 h 91.9 7.8 99.7 
Base hydrolysis using 
0.1 N NaOH (at 25°C) 
24 h 65.8 32.5 98.3 
Oxidative degradation 
using 3 % H2O2 (at RT) 
24 h 97.2 3.5 100.8 
Photolytic degradation 
(controlled) 
4 days 99.4 0.44 99.8 
Photolytic degradation  
(un-controlled) 
4 days 98.5 0.88 99.4 
Thermal degradation  
at 60°C 
5 days 99.3 0.34 99.6 
 





The precision of the method for assay 
determination, the %RSD is below 0.47 and it was 
well within the acceptance range. The precision of the 
method for related compound determination, the 
%RSD is less than 4.8%. The %RSD of Meropenem 
assay results obtained in the intermediate precision is 
below 1.0 and related substance method is found be 
less than 15%. The method precision results are given 
in Table 3 and 4. 
 
Limit of detection and Limit of quantitation 
The LOD and LOQ for Meropenem and related 
compounds are found to be 0.09 and 0.32 µg/ml 
 
 
Fig. 5 — System suitability & selectivity chromatogram of Meropenem. 
 
 
Fig. 6 — Stress study chromatograms. 
 




respectively. The results are given in Table 5. Method 
sensitivity chromatograms (LOD and LOQ) were 
shown in Fig. 7. 
Linearity 
Calibration curve obtained by least square 




Fig. 7 — Method sensitivity chromatograms (a) LOQ and (b) LOD. 
 
Table 3 — Method precision results for related substances method 
Preparation Impurity-A Impurity-B Impurity-C Total Impurities 
Preparation-1 0.112 0.105 0.093 0.712 
Preparation-2 0.109 0.101 0.096 0.701 
Preparation-3 0.111 0.104 0.089 0.719 
Preparation-4 0.113 0.111 0.099 0.722 
Preparation-5 0.108 0.103 0.092 0.718 
Preparation-6 0.115 0.106 0.101 0.714 
Average 0.111 0.105 0.095 0.714 
Std dev 0.003 0.003 0.005 0.007 
%RSD 2.32 3.24 4.75 1.04 
 
 













Table 5 — Method sensitivity results 








0.0948 0.0894 0.0882 0.0714 
LOD S/N 4.5 6.0 4.0 8.2 
LOQ  
(µg/ml) 
0.316 0.298 0.294 0.238 
LOQ S/N 13.8 16.9 14.1 24.2 
LOQ Precision 
%RSD (n=6) 
2.1 3.8 2.3 1.2 
 




concentration showed linear relationship with 
regression coefficient of 0.999 for Meropenem and  
≥ 0.997 for related compounds respectively over the 
calibration ranges tested. The results are demonstrated 
that an excellent correlation between the peak area 
and concentration. The linearity results are given in 
Table 6 and 7 and the obtained calibration curve is 
given in Fig. 8 and 9. 
 
Accuracy 
The accuracy of the assay method is determined in 
percentage recovery of Meropenem from bulk drug 
samples ranged from 99.9% to 100.0%. The 
percentage recovery of the five impurities from bulk 
drug samples ranged from 95.9% to 104.2% and the 
results are shown in Table 8 and 9. 
Solution stability 
The %RSD of Meropenem and its related 
compounds peak areas were found be less than 2% 
and 10% respectively. The stability of Meropenem 
 
Table 7 — Linearity results of assay method 






Correlation ( r ) 0.9999 
Regression ( r2 ) 0.9999 
slope ( m ) 43363 
Y-intercept ( c ) -152893 
% Y-intercept -0.3 
 










0.316 12909 0.298 18572 0.294 16430 0.238 20492 
0.537 21238 0.507 30554 0.500 27029 0.405 33712 
1.074 41643 1.013 59909 1.000 52999 0.809 66102 
1.613 66213 1.521 95255 1.500 86268 1.215 106102 
2.137 88284 2.015 123413 1.988 109588 1.609 130526 
Correlation ( r ) 0.9994 Correlation ( r ) 0.9994 Correlation ( r ) 0.9987 Correlation ( r ) 0.9978 
Regression ( r2 ) 0.9988 Regression ( r2 ) 0.9989 Regression ( r2 ) 0.9975 Regression ( r2 ) 0.9957 
slope ( m ) 41600 slope ( m ) 61783 slope ( m ) 56048 slope ( m ) 82320 
Y-intercept ( c ) -1174.7 Y-intercept ( c ) -614.7 Y-intercept ( c ) -746.5 Y-intercept ( c ) 988.6 




Fig.8 — Linearity plots of related substances. 




sample solution by assay method and also related 
substances method are stable up to 48 h at 5 °C. 
 
Robustness 
The robustness of the method was determined as a 
measure of the analytical method capability, which is 
to be unaffected by small variation in method 
parameters
[15]
. The variations such as flow rate by  
± 0.2 ml/min, variation in column temperature by  
± 5°C and slight variation in wavelength ± 2 nm. At 
these changed conditions the system suitability was 
evaluated at each condition. In all the conditions, the 
resolution between critical pair was greater than  
1.7 and tailing factor of Meropenem peak is found  
be less than or equal to 1.5 (Results are given in  
Table 10). 
Conclusions 
The developed gradient stability-indicating 
reversed phase high performance liquid 
chromatographic method (RP-UHPLC) method has 
shown excellent selectivity between impurities along 
with Meropenem and objective of the development is 
achieved on short column i.e., RRLC Zorbax eclipse 
plus C18 100 x 4.6 mm, 3.5 µm to reduce the run time 
of the method to have a quick turnaround time for the 
routine samples analysis, which was more economic 
and environment friendly to minimize the HPLC 
effluent waste when compare to other reported 
conventional HPLC methods. The developed method 
is 15 min of the run time and the Meropenem and its 
related compounds were eluted within 10 min. The 
present method was found to be stability-indicative 
for assay determination and validation data indicates, 
method was simple, linear gradient method and it was 
found to be specific, precise, linear and accurate. The 
main advantage of developed method is suits eco-
friendly method than published methods in terms of 
analysis time, cost, effluent waste and outcome of the 
analysis. Hence, it can be used successfully for the 
routine analysis of Meropenem API samples and for 
analysis of stability samples obtained during 
accelerated stability study. 
Table 9 — Results of accuracy for RS method 
Compound Name Amount added  
(in µg/ml) 
Amount recovered  
(in µg/ml) 
% Recovery 
Impurity-A 0.298 0.311 104.2 
1.013 0.980 96.7 
2.015 2.007 99.6 
Impurity-B 0.294 0.306 104.2 
1.000 0.959 95.9 
1.988 1.969 99.0 
Impurity-C 0.238 0.237 99.5 
0.809 0.791 97.7 








Table 8 — Results of accuracy for assay method 
Compound Name Level  
(%) 
Amount added  
(in µg/ml) 
Amount recovered  
(in µg/ml) 
% Recovery 
Meropenema 80 833.6 833.7 100.0 
100 1042.0 1040.5 99.9 
120 1250.4 1249.1 99.9 
aAssay of Meropenem concentration (1000 µg/ml). 
 
Table 10 — Results of robustness evaluation data 
Chromatographic 
changes 




Flow rate (ml/min)    
0.8 2.3 1.42 89000 
1.2 1.6 1.03 123657 
Temperature (°C)    
20 2.2 1.36 98234 
30 1.8 1.13 110498 
Wavelength(nm)    
218 1.9 1.09 106256 
222 1.9 1.09 108381 
a Resolution between impurity-B and C peaks 
bMeropenem peak 
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